Brainsway Ltd. BWAY 深 滬
交易中 08-13 10:13:07 美东时间
12.97
+0.780
+6.40%
華盛通- 最 高13.01
- 今 開12.86
- 成交量 5.70万股
- 最 低 12.86
- 昨 收 12.19
- 總市值 2.45亿
- 52周最高 13.655
- 市盈率 靜 117.16
- 換手率 0.30%
- 52周最低 7.06
- 委 比 43.88%
- 總股本 1889.49万
- 歷史最高 13.655
- 量 比 12.78
- 振 幅 1.23%
- 歷史最低 1.38
- 每 手 1
- 風險率 1.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BrainsWay Raises FY2025 Sales Guidance from $49.000M-$51.000M to $50.000M-$52.000M
BrainsWay (NASDAQ:BWAY) raises FY2025 sales outlook from $49.000 million-$51.000 million to $50.000 million-$52.000 million.
今天 19:32
BrainsWay Q2 EPS $0.05, Inline, Sales $12.632M Beat $12.357M Estimate
BrainsWay (NASDAQ:BWAY) reported quarterly earnings of $0.05 per share which met the analyst consensus estimate. This is a 150 percent increase over earnings of $0.02 per share from the same period last year. The
今天 19:32
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
今天 16:32
BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals
BrainsWay has announced funding for two new Continuing Medical Education (CME) courses aimed at enhancing clinicians' knowledge and confidence in using Transcranial Magnetic Stimulation (TMS). The courses, led by expert faculty, focus on the clinical evidence for TMS, the differences between Deep TMS™ and traditional TMS, and practical integration into clinical practice. Both courses provide up to 0.5 AMA PRA Category 1 Credits™ and are available...
07-30 13:02
BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025
BrainsWay Ltd. will report its second quarter 2025 financial results and operational highlights before the U.S. market open on August 13, 2025. A conference call and webcast will be held at 8:30 AM Eastern Time to discuss the results. The call is accessible via dial-in numbers (US: 1-877-300-8521, Intl: 1-412-317-6026, Israel: 1-80-921-2373) with conference ID 10201287, and a replay will be available on the company’s website.
07-30 12:00
Bowman Awarded Phase II Geospatial Assignment for Large-Scale Federal Project
Bowman Consulting Group Ltd. has been awarded a Phase II contract to continue providing aerial acquisition and orthoimagery services for the USDA's National Resource Inventory (NRI) program, covering 11.2 million acres nationwide. The NRI program assesses land, soil, water, and natural resources. Bowman's advanced technologies and efficient data processing have improved project delivery, supporting USDA's large-scale demands. This contract reflec...
06-25 13:20
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
Preliminary results from a BrainsWay study show that an accelerated Deep TMS protocol using iTBS for treating major depressive disorder achieved comparable efficacy to standard Deep TMS, with shorter sessions and a faster median time to remission. The accelerated group completed 5 daily sessions over 6 days, with HDRS-21 scores reduced by 18.9 points, response rates of 87.8%, and remission rates of 78.0%. Sessions lasted under 10 minutes, compare...
06-11 11:30
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
BrainsWay Ltd. announced its sponsorship of the 2025 Clinical TMS Society Annual Meeting, showcasing its Deep Transcranial Magnetic Stimulation (Deep TMS™) technology. The event will feature a clinical education session presenting new data on an accelerated Deep TMS protocol, as well as posters highlighting studies on smoking cessation, adolescent depression, and optimal H1 coil positioning for treating depression. Attendees can also experience h...
06-10 12:00
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:BWAY) with a Buy and maintains $16 price target.
06-09 20:27
